Recent News

ASCO 2019: Trial Update on Cytoreductive Nephrectomy for Intermediate-Risk Metastatic Renal Cancer

ASCO 2019: Enfortumab Vedotin in Advanced Urothelial Cancer

Dalantercept Plus Axitinib in Advanced Clear Cell Kidney Cancer

ASCO 2019: Does Adding Bevacizumab to Standard Treatment Improve Survival in Urothelial Carcinoma?

ASCO 2019: KEYNOTE-426 Subgroup Analysis of Pembrolizumab Plus Axitinib in Kidney Cancer

ASCO 2019: Pazopanib After Metastasectomy in Renal Cell Carcinoma

Spontaneous Shrinkage in Renal Cell Carcinoma Tumors

AUA 2019: Timing of Nephrectomy and Outcomes in pT3 Renal Cell Carcinoma

Combination of Avelumab/Axitinib Approved by FDA for Advanced Renal Cell Carcinoma

Rare Benign Mass Mimics Recurrent Renal Cell Carcinoma: Case Report

Novel Approach to Predicting Adverse and Beneficial Effects of Immunologic Interventions

Immune-Related Adverse Events in Metastatic Kidney Cancer: A Sign of Treatment Success?

FDA Approves Pembrolizumab Plus Axitinib in Advanced Kidney Cancer

Does Bladder-Sparing Therapy Plus Vinorelbine Improve Survival in Cisplatin-Ineligible Patients?

Accelerated FDA Approval Granted to Erdafitinib for Metastatic Urothelial Carcinoma

AACR 2019: Can B Cells Predict Response to Immunotherapy in Renal Cell Carcinoma?

EAU Congress 2019: Early Menopause in Smokers and Bladder Cancer Risk

Tumor-Lysis Syndrome in Patients With Genitourinary Cancers

Nivolumab in Metastatic Kidney Cancer in ‘Real-World Setting’

Predicting Outcomes With Lung Immune Prognostic Index

Postoperative Chemotherapy Plus Radiotherapy for Locally Advanced Bladder Cancer

2019 GU Symposium: Subgroup Analysis of Avelumab + Axitinib in JAVELIN Renal 101 Trial

2019 GU Symposium: Tivozanib Versus Sorafenib in Advanced Renal Cell Carcinoma

Priority Review Granted to Pembrolizumab Combination in First-Line Therapy for Advanced Kidney Cancer

FDA Accepts for Priority Review Avelumab and Axitinib Combination for Advanced Kidney Cancer

2019 GU Symposium: Cabozantinib vs. Everolimus in METEOR Trial of Kidney Cancer

2019 GU Symposium: Pembrolizumab Plus Axitinib Versus Sunitinib in Advanced Kidney Cancer

Risk Factors for Renal Cell Carcinoma Related to Obesity

Computer-Designed Protein Mimics Interleukin-2 With Less Toxicity

Kidney Cancer and Rare Genetic Tumor Syndrome

Sorafenib Versus Other Targeted Agents in Metastatic Renal Cell Carcinoma

Northwestern Medicine Receives $10 Million Gift to Create Urologic Cancer Institute

TKIs After Immunotherapy Failure in Metastatic Renal Cell Carcinoma

Predicting Prognosis for Patients With Metastatic Papillary Renal Cell Carcinoma

Clinical Trial of Personalized Vaccine in Kidney Cancer Commences

Validated Risk Model Integrates Molecular Features in Advanced Renal Cancer